Study of HIPEC, NIPS, and immunotherapy for stomach cancer with spread to the abdomen
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of heated chemotherapy placed directly in the abdomen (HIPEC), chemotherapy given through a vein and the abdominal cavity (NIPS), and an immunotherapy drug (tislelizumab) for people with stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink the cancer enough to allow for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had any chemotherapy, radiation, or other cancer treatment before.
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction adenocarcinoma that is HER2-negative and has a PD-L1 CPS score of 1 or higher.
- A laparoscopy (a small camera in the abdomen) shows either cancer cells in the abdominal fluid or small spots of cancer on the abdominal lining with a PCI score of 10 or less.
- Your cancer has not spread to other distant organs.
- You are in good enough health with adequate blood cell counts, liver and kidney function, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This Phase 2 trial studies a combination treatment for stomach (or stomach-to-esophagus) cancer that has spread to the belly lining. It tests whether adding the immunotherapy drug sintilimab to a procedure called HIPEC can improve outcomes for people who have not had prior treatment.
This trial tests a new treatment combination for locally advanced stomach cancer. First, you would receive a heated chemotherapy wash inside your abdomen (HIPEC). Then you would get the immunotherapy drug serplulimab plus standard chemotherapy (SOX or XELOX) before surgery, to shrink the tumor and improve outcomes.
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Hear when a new Gastric Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.